Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Recurrence × TQ-B3525 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Lymphoma 1

Interventions

Cyclophosphamide 39 fludarabine 28 Dexamethasone 23 venetoclax 19 Cytarabine 17 Rituximab 14 pembrolizumab 12 fludarabine phosphate 12 Filgrastim 12 Etoposide 11 Gemcitabine 10 Lenalidomide 9 Granulocyte Colony-Stimulating Factor 9 carfilzomib 8 Vincristine 8 Topotecan 8 Interleukin-2 8 Decitabine 8 pomalidomide 7 Nivolumab 7 Melphalan 7 Everolimus 7 Doxorubicin 7 Calcium Dobesilate 7 Bortezomib 7 Azacitidine 7 Vorinostat 6 Methotrexate 6 Injections 6 Carboplatin 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03510767 2023-04-14

A Study of TQ-B3525 on Tolerance and Pharmacokinetics

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1 Unknown

Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡